Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-Oncology"
DOI: 10.1093/neuonc/now257
Abstract: Background The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a… read more here.
Keywords: newly diagnosed; safety; abt 414; diagnosed glioblastoma ... See more keywords
Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: [RETRACTED].
Sign Up to like & getrecommendations! Published in 2018 at "Cornea"
DOI: 10.1097/ico.0000000000001635
Abstract: PURPOSE To report the first histological characterization of microcyst-like epithelial keratopathy (MEK) associated with depatuxizumab mafodotin (ABT-414). METHODS Case report. RESULTS A 35-year-old man with glioblastoma multiforme participating in a phase III trial of the… read more here.
Keywords: depatuxizumab mafodotin; mafodotin abt; histological characterization; abt 414 ... See more keywords
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835920907543
Abstract: Background: The aim of this study was to prospectively analyse, for the first time worldwide by in vivo clinical confocal microscopy (CCM), corneal side effects secondary to the use of epidermal growth factor receptor (EGFR)… read more here.
Keywords: corneal side; microscopy; abt 414; clinical confocal ... See more keywords
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2003
Abstract: 2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is amplified (amp) in ~50% of GBMs and is a compelling therapeutic target. ABT-414 is… read more here.
Keywords: efficacy analysis; analysis; analysis abt; abt 414 ... See more keywords
Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
Sign Up to like & getrecommendations! Published in 2021 at "Arquivos brasileiros de oftalmologia"
DOI: 10.5935/0004-2749.20220039
Abstract: The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414… read more here.
Keywords: depatuxizumab mafoditin; abt 414; ocular surface; surface toxicity ... See more keywords